Opus Point Partners Management LLC Cuts Holdings in Ultragenyx Pharmaceutical Inc (RARE)

Share on StockTwits

Opus Point Partners Management LLC reduced its stake in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 13.9% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,291 shares of the biopharmaceutical company’s stock after selling 1,181 shares during the period. Opus Point Partners Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $372,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Profund Advisors LLC raised its holdings in Ultragenyx Pharmaceutical by 5.6% during the first quarter. Profund Advisors LLC now owns 16,653 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 889 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 2.8% in the first quarter. American Century Companies Inc. now owns 36,720 shares of the biopharmaceutical company’s stock valued at $1,872,000 after buying an additional 997 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Ultragenyx Pharmaceutical by 5.0% in the first quarter. Wells Fargo & Company MN now owns 24,200 shares of the biopharmaceutical company’s stock valued at $1,234,000 after buying an additional 1,149 shares in the last quarter. RMB Capital Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 3.3% in the first quarter. RMB Capital Management LLC now owns 45,178 shares of the biopharmaceutical company’s stock valued at $2,304,000 after buying an additional 1,445 shares in the last quarter. Finally, Verity Asset Management Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 26.4% in the first quarter. Verity Asset Management Inc. now owns 7,245 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 1,512 shares in the last quarter. Institutional investors and hedge funds own 96.04% of the company’s stock.

Several analysts have issued reports on RARE shares. JMP Securities boosted their target price on shares of Ultragenyx Pharmaceutical from $70.00 to $74.00 and gave the company an “outperform” rating in a research note on Wednesday, April 18th. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Wedbush reaffirmed a “positive” rating and set a $71.00 price objective (up previously from $64.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, April 18th. Cowen reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, April 18th. Finally, Barclays raised shares of Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $62.00 to $74.00 in a research report on Friday, May 11th. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $71.26.

In other news, EVP Karah Herdman Parschauer sold 1,226 shares of the company’s stock in a transaction on Thursday, June 21st. The shares were sold at an average price of $82.77, for a total value of $101,476.02. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Theodore Alan Huizenga sold 1,338 shares of the stock in a transaction on Wednesday, June 13th. The stock was sold at an average price of $76.97, for a total transaction of $102,985.86. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,003 shares of company stock valued at $2,275,942. 8.40% of the stock is owned by corporate insiders.

Shares of Ultragenyx Pharmaceutical opened at $76.87 on Friday, MarketBeat reports. Ultragenyx Pharmaceutical Inc has a twelve month low of $41.67 and a twelve month high of $86.10.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, May 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.81. The firm had revenue of $10.68 million during the quarter, compared to analyst estimates of $56.58 million. During the same quarter in the previous year, the firm posted ($1.63) earnings per share. equities analysts expect that Ultragenyx Pharmaceutical Inc will post -5.32 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply